PPAR- α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia

Irisin is related to insulin resistance and metabolic disorders. the physiologic effects of irisin are partially mediated through peroxisome proliferator-activated receptor-α (ppar-α). we investigated the effect of fenofibrate,a ppar-α agonist,on serum irisin in type 2 diabetes patients with hypertriglyceridemia. this study evaluated cross-sectional and interventional studies of 25 type 2 diabetes patients with hypertriglyceridemia (group a) and 40 controls (group b). group a was treated with fenofibrate (200 mg/day) for 8 weeks. serum irisin and clinical characteristics were examined. serum irisin was significantly higher in group a compared with group b (45.15±10.48 versus 35.38±9.97 ng/ml,p<0.001) and correlated with body mass index (r=0.314,p=0.011),fasting blood glucose (r=0.399,p=0.001),total cholesterol (r=0.256,p=0.040),and high-density lipoprotein cholesterol (r=0.247,p=0.047). in multiple regression analysis after controlling for confounders,only fasting blood glucose (β=5.615,p<0.001) and high-density lipoprotein cholesterol (β=19.483,p<0.001) were independently related to serum irisin. after 8 weeks of fenofibrate treatment,serum irisin significantly decreased in group a compared with baseline (45.15±10.48 versus 38.74±12.54 ng/ml,p=0.011). conclusively,fenofibrate decreased serum irisin in type 2 diabetes patients with hypertriglyceridemia,indicating that ppar-α agonists may protect against metabolic disorders by improving irisin resistance. © 2015 xiaomeng feng et al.